Influenza Report
 
Download pdf
 

 

 

   

²Ä¤­³¹: ¥þ²y©Ê¤j³W¼Ò¬Ì¯gªº·Ç³Æ

Author(s) §@ªÌ:

Gustavo Reyes-Terán and René Gottschalk
Translator(s) ĶªÌ: ´^¹Å»¨ Pang Ka Ho
Editor (Chinese Version)
½sªÌ(¤¤¤åª©¥»):
­³§®©yMary M.Y. Waye
English version

 

 

 

 

¾É½×
(ºñ¦â³sµ²: §K¶O¥þ¤å¾\Äý)

 

´¿¸gµo¥Í¹Lªº¥þ²y©Ê¤j³W¼Ò¬y¦æ©Ê·P«_¬Ì¯g

¦³¤T³õ¥þ²y©Ê¤j³W¼Ò¬y¦æ©Ê·P«_¬Ì¯g´¿¸gÃzµo¹L¡A³o¤T³õ¬Ì¯g³£¬O¥Ñ¥Ò«¬¬y·P¯f¬r©Ò¤Þ°_ªº¡C·í³Ì¤Ö¤@ºØ¯f¬rªí­±³J¥Õ--¦å²Ó­M¾®¶°¯À(haemagglutini)©M¯«¸g®ò»ÄžJ (neuraminidase)µo¥Í¬ðÅÜ¡A¨S¦³¤H¯à¹ï³o·sºtÅÜ¥X¨Óªº¯f¬r¦³§K¬Ì¤O¡C¦pªG¯f¬rºtÅܦ¨¤H¶Ç¤H¤Î¯à¦b¤HÅ餺¤j¶q½Æ»s¤w­P²£¥ÍÄY­«¯e¯f¡A¨º»ò¤@³õ¥þ²y©Ê¤j³W¼Ò¬Ì¯g´N·|Ãzµo¡C³o¼Ëªº¨Æ´¿¦b1918(H1N1¦è¯Z¤ú«¬¬y·P)¡B1957(H2N2¨È¬w«¬¬y·P)¤Î1968(H3N2­»´ä«¬¬y·P)¦~µo¥Í¹L¡C«O¦u¦ô­p¦b1918¦~¤@¬Ì¤¤¡A¤j¬ù¦³¤G¤d¦Ü¥|¤d¸U¤H¦º¤`¡C¦ý¬O±q³Ìªñ¦b«D¬w¤Î¨È¬wªº¬ã¨s«ü¥X·í¦~ªº¦º¤`¼Æ¦r¦n¥i¯à±µªñ¤­¤d¸U¦Ü¤@»õ(Johnson 2002)¡C

¬y·P±M®a«ü¥X­YªG¬Ì¯g³æ³æ¦b¤u·~¤Æ°ê®aÃzµo¡A¨â¦~¤º·|¦³¤@»õ¤T¤d¸U¦Wªù¶E¯f¤H¡A¤G¦Ê¸U¦í°|¤H¼Æ¤Î¤»¤Q¤­¸U¤H¦º¤`¡A³o½ÄÀ»­YªG¦bµo®i¤¤°ê®aµo¥Í«áªG±N·|§óÄY­«(WHO 2004)¡C­YªG1918¦~ªº¬Ì¯g¦b²{¤µµo¥Í¹w­p¥þ²y·|¦³¤@»õ¤K¤d¸U¦Ü¤T»õ¤»¤d¸U¤H¦º¤`(Osterholm 2005)¡C

 

H5N1¦b¥þ²y©Ê¤j³W¼ÒÃzµoªº«Â¯Ù

ª½¦Ü2006¦~1¤ë¡A¦b»·ªF¦³¤E­Ó°ê®a¤w¦³³ø§i¦b®a¸V¤¤Ãzµo°ª­P¯f©ÊªºH5N1¸V¬y·P¯f¬r¡C¸Ó¤E­Ó°ê®a¬°¥_Áú¡B¶V«n¡B¤é¥»¡B®õ°ê¡B¬Z®H¹ë¡B¼d°ê¡B¦L¥§¡B¤¤°ê¤Î°¨¨Ó¦è¨È¡C¦b¤é¥»¡B°¨¨Ó¦è¨È©M¥_ÁúªºÃzµo¤w¦¨¥\±o¨ì±±¨î¡A¦ý¯f¬r¦b¬Y¨Ç¨ü¼vÅTªº°ê®a¤wÅܦ¨­·¤g¯f¡C¦bªF«n¨ÈªºÃzµo¤w³y¦¨¶W¹L¤@»õ¤­¤d¸U°¦¸V³¾¦º¤`©MÄY­«¼vÅT·í¹A·~¡A¤×¨ä¹ï¨º¨Ç¨Ì¿à¤p«¬®aªÙ¦¡¹A³õ§@¬°¦¬¤J¤Î³­¹ªº­¥°Ï¹A¥Á¼vÅT§ó¬Æ¡C

³ÌªñÃzµo¦b«Xù´µ¡B«¢ÂħJ¡B¤g¦Õ¨ä¡Bù°¨¥§¨È¤Î§Jù¦a¨ÈªºH5N1¸V¬y·P¯f¬r©M¤§«e¨ä¥L¦a°Ï©ÒÃzµoªºH5N1¸V¬y·P¯f¬rÄݦP¤@«~ºØ¡A³o´£¨Ñ¤F¸V¬y·P¤w´²¼½¶}¥hªºÃÒ¾Ú(WHO 2005a, WHO 2005b)¡C

¤j³¡¥÷¤HÃþ·P¬V¸V¬y·P(H5N1)ªº­Ó®×³£¥Ñª½±µ±µÄ²¯f¬r©Î¦º¥hªº¸V³¾©ó­¥°Ï©Ò­P¡A¦³¤»­Ó°ê®a¤wÃҹ꦳¤HÃþ·P¬V¸V¬y·P­Ó®×¡A¥]¬A¶V«n¡B®õ°ê¡B¬Z®H¹ë¡B¦L¥§¡B¤¤°ê¤Î¤g¦Õ¨ä(¸Ô±¡¬Ýªí1)¡C¥@½Ã·|©w´Á§ó·s¤HÃþ·P¬V¸V¬y·P½T¶E­Ó®×¼Æ¦r©ó¥@½Ãºô¯¸ (WHO 2005c)¡C

ªí1. ª½¦Ü2006¦~1¤ë25¤é®Ú¾Ú¥@½Ã³ø§i²Ö¿n¤HÃþ·P¬V¸V¬y·P½T¶E­Ó®×¼Æ¦r(WHO 2005c)*
 
½T¶E­Ó®×**
¦º¤`¼Æ¦r
¶V«n
93
42
®õ°ê
22
14
¬Z®H¹ë
4
4
¦L¥§
19
14
¤¤°ê
10
7
¤g¦Õ¨ä
4
2
Á`¼Æ
152
83

* ¥@½Ã³ø§i¥u®Ú¾Ú¹êÅç«Ç½T¶E­Ó®×
** ½T¶E­Ó®×Á`¼Æ¥]¬A¦º¤`¼Æ¦r

ªñ´Á¬ã¨s«ü¥X1918¦~Ãzµoªº¬y·P¯f¬r¥i¯à¤£¬O¥Ñ¤HÃþ«¬¬y·P¯f¬rºtÅÜ¥X¨Ó(¤£¹³1957©M1968¦~ªºÃzµo)¡A¦Ó¬O¥Ñ¸V³¾Ãþ«¬¬y·P¯f¬rºtÅܦ¨¥i·P¬V¤HÃþ(Taubenberger 2005)¡C¬ã¨s¥ç¦³ÃÒ¾Ú«ü¥X1918¦~ªº¯f¬r¤§©Ò¥H¦³·¥°ªªº­P¯f©Ê©M¸Ó¯f¬r¬O¥i·P¬V¤HÃþªº¸V³¾Ãþ«¬¬y·P¯f¬r¦³Ãö¡C1918¦~ªº¯f¬r©Mªñ´Á¬y³qªº°ª­P¯f©Ê¤Î­P©Rªº¸V¬y·P¯f¬r³£¦³¥O¤H¶O¸Ñªº¬Û¦ü©Ê¡A´N¬O¦³¤@©w¼Æ¶q»E¦Xª«žJ³J¥Õ(polymerase protein)ªº§ïÅÜ(Taubenberger 2005)¡A©Ò¥H­È±o§Ú­ÌÃöª`¡C

H5N1¬O¤@ºØ±q°ò¦]¾Ç¤W¦­¤w¦s¦b¡B¹ï¤HÃþ¦³·¥°ªªº­P¯f©Ê©M¥i¯àºt¤Æ±o¯à¦³®Ä¦a¤H¶Ç¤Hªº¯S©Ê¡C¥@½Ã­«¥Ó©ó1997¦~¹ï¥þ¥@¬É¬°¤U¤@¦¸¸V¬y·P¤j³W¼ÒÃzµo§@·Ç³Æªº©IÆ~¡A³o©IÆ~³Qµø¬°µL¥iÁקKªº(BWHO 2004)¡C¥@½Ã¥ç©ó2005¦~4¤ë§ó·s¹w¨¾¸V¬y·P¤j³W¼ÒÃzµoªº­p¹º(WHO 2005d)¡C

 

¸V¬y·P¤j³W¼ÒÃzµoªº·Ç³Æ

¨Æ¥ý­p¹º¯à´î¤Ö©M´îºC¸V¬y·Pªº¶Ç¬V¤Î¶Ç¼½¡A¥ç¥i´î§C¦í°|¤Î¦º¤`¤H¼Æ¡C¨Æ¥ý·Ç³Æ«h¯àºû«ùÃzµo®Éªº¥²»ÝÂåÀøªA°È©M­°§C¸V¬y·P¹ï¸gÀÙ¤W¤ÎªÀ·|¤Wªº½ÄÀ»(WHO 2004)¡C

®Ú¾Ú¬y¦æ¯f¾Ç¡A¬Ì¯gÃzµoªº³Ì¤j½ÄÀ»·|¦b²Ä¤T¥@¬É°ê®a¤W¡A¦]¬°³o¨Ç°ê®a¥u¦³¦³­­ªº¬Ì±¡ºÊ±±¯à¤O©MÂåÀø¸ê·½¡A¦P®É³o¨Ç°ê®aªº¤H¤f´¶¹M¦³¸û§Cªº°·±d¤ÎÀç¾i¤ô¥­(WHO 2004)¡C

 

¬Ì¯g¤j³W¼ÒÃzµo¶g´Á

¬°¤F¤¶©w¦b¯S©w±¡ªp¤Uªº¤@³s¦ê¬ÛÀ³±¹¬I¡A¥@½Ãªº¥þ²y¬y·P·Ç³Æ­p¹º(WHO 2005d)¤À¥X´X­Ó¤£¦Pªº®É´Á¡C¨C¤@´Á³£»P°ê»Ú¤Î°ê¤ºªº¬ÛÀ³±¹¬I¦³ÃöÁp¡C®Ú¾Ú·í¦aªº¬y¦æ¯f¾Ç¡A°ê¤º¦b¨C¤@´Áªº¬ÛÀ³±¹¬I·|¦A²Ó¤À¡C¥@½Ã±j¯P«Øij¦U°ê¦bµo®i¤Î§ó·s°ê¤º©ó¤£¦P®É´Áªº­p¹º®ÉÀ³°Ñ·Ó¨ä¥þ²y¬y·P·Ç³Æ­p¹º¡C¦U®É´Áªº·§¬A¤w¦C¥X¦bªí¤G¡C²{®É(2006¦~1¤ë)¥@¬É¥¿³B©ó²Ä¤T´Á¡A¤@ºØ·sªº¬y·P°Æ«¬¯f¬r¤w¥O¤HÃþ¬V¯f¡A¦ý©|¥¼µo®i¦¨¯à¦³®Ä¦a¤H¶Ç¤H¡C

 

ªí2. ®Ú¾Ú¥@½Ãªº¥þ²y¬y·P·Ç³Æ­p¹º©ó2005¦~©Ò¹º¥Xªº´X­Ó¤£¦P®É´Á
¶g´Á/®É´Á ±¡ªp
¨â¦¸Ãzµo¤§¶¡ªº¶g´Á  
²Ä¤@´Á ¨S¦³·sªº¬y·P°Æ«¬¯f¬rµo²{¦b¤H¨­¤W¡A¦ý¥i¯à¤w¦b°Êª«¨­¤W¦s¦b¡C¦pªG¯f¬r¯u¬O¦b°Êª«¨­¤W¦s¦b¡A¶Ç¬Vµ¹¤Hªº­·ÀIa¥ç¬Û·í¤§§C¡C
²Ä¤G´Á ¤´µM¨S¦³·sªº¬y·P°Æ«¬¯f¬rµo²{¦b¤H¨­¤W¡A¦ý¬O¦b°Êª«¨­¤W¬y³qªº¬y·P¯f¬r¦³¬Û·íªº­·ÀIa¶Ç¬Vµ¹¤H¡C
Ãzµoĵ§Ù¶g´Á  
²Ä¤T´Á ¤HÃþ¤w³Q·sªº¬y·P¨È«¬¯f¬r·P¬V¡A¦ý¨Ã¨S¦³¤H¶Ç¤Hªº¸ñ¶H©Î³Ì¦h¥u¬O¦³·¥¤Ö¼Æ¦]ºò±K±µÄ²¦Ó¶Ç¬Vªº­Ó®×¡C
²Ä¥|´Á ¤@¤p¸s¤H¦b°ª«×§½³¡ªº¦a°Ï¦]¦³­­«×ªº¤H¶Ç¤H¦Ó¨ü·P¬V¡A³oÅã¥Ü¯f¬r¥ç¥¼¯à¦³®Ä¦a¤H¶Ç¤H¡Cb
²Ä¤­´Á ¤@¤j¸s¤H¦]¤H¶Ç¤H¦Ó¨ü·P¬V¡A¦ý¤´µo¥Í¦b§½³¡¦a°Ï¤W¡C³oÅã¥Ü¯f¬r¤w¾AÀ³¦b¤H¨­¤W¡A¦ý¨Ã¨S¦³§¹¥þªº·P¬V¤O¡C(¬Û·í¤jªºÃzµo¦M¾÷)b
Ãzµo¶g´Á  
²Ä¤»´Á ¥þ­±Ãzµo´Á: ´¶¹M¤H¤f¤£Â_¦Ó¥B«ùÄò¦a¨ü·P¬V¡Cb
«áÃzµo¶g´Á ªð¦^²Ä¤@´Á¡C

a. ²Ä¤@´Á»P²Ä¤G´Áªº°Ï§O¦b©ó¤HÃþ¥Ñ°Êª«¨­¤W¬y³qªº¬y·P¯f¬r¦Ó¨ü·P¬Vªº­·ÀI¡A³o°Ï§O¬O®Ú¾Ú²{®Éªº¬ì¾Çª¾ÃѦөw¤Uªº¦]¼Æ¡C³o¨Ç¦]¼Æ¥]¬A: ¦b°Êª«©M¤HÃþ¨­¤Wªº­P¯f©Ê¡B¯f¯gµo¥Í¦b¦Û¾iÁÙ¬O¦b³¥¥Íªº°Êª«¤W¡B¯f¬r¬O¦a¤è°Êª«¯fÁÙ¬O¬y¦æ°Êª«¯f¡B¦a²z¤W¶°¤¤ÁÙ¬O¤À´²¡B¯f¬r°ò¦]²Õ©M¨ä¥L¬ì¾Ç¸ê°T¡C

b. ²Ä¤T´Á¡B²Ä¥|´Á©M²Ä¤­´Áªº°Ï§O¦b©ó¹ï¥þ­±Ãzµo­·ÀIªºµû¦ô¡A³o°Ï§O¥ç¬O®Ú¾Ú²{®Éªº¬ì¾Çª¾ÃѦөw¤Uªº¦]¼Æ¡C³o¨Ç¦]¼Æ¥]¬A: ¶Ç¬V²v¡B¦a²z¦ì¸m»P´²¼½¡B¯e¯fªºÄY­«©Ê¡B¤HÃþ°ò¦]ªº¦s¦b(¦pªG¬O¥Ñ°Êª«±o¥Xªº)¡B¯f¬r°ò¦]²Õ©M¨ä¥L¬ì¾Ç¸ê°T¡C

 

¨â¦¸Ãzµo¤§¶¡ªº¶g´Á»PÃzµoĵ§Ù¶g´Á

¯f¬rºÊ±±

¯f¬rºÊ±±³Q©w¬°¤£¶¡Â_¤Î¦³¨t²Î¦a¦¬¶°¡B¤ÀªR©M¸ÑÄÀ¯S©wµ²ªGªº¼Æ¾Ú¥Î¥H­p¹º¡B¼i¦æ©Mµû¦ô¤½²³°·±d±¹¬I¡A¦Ó¤£¥u¬O¯Âºé¦¬¶°¼Æ¾Ú(Flahault 1998)¡C¦]¦¹¤@­Ó¾A®É¡B¦³¥Nªí©Ê©M¦³®Ä²vªººÊ±±¨t²Î¬O±±¨î¶É¦V©ó¤j³W¼ÒÃzµoªº¶Ç¬V¯fªº°ò¥Û(PPHSN 2004)¡C

¬°¤F¯à¹îı¦]·s«¬¬y·P¯f¬r¦Ó¤Þµo¥X¤@¸s¤H¦³¤£´M±`±w¯f­Ó®×¼Æ¥Ø¡A¦U°ê¥²¶·¦³¤@­Ó¤HÃþ¬Ì¯f¹w¦­Äµ§i¨t²Î¡C³q¹L°Ñ»P¥þ²y¬y·PºÊ±±ºôµ¸¡A¦U°ê³£·|¹ïµo²{¬y·P¯f¬r¥]¬A¼ç¦bÃzµo¦M¾÷§@¥X°^Äm¡CºÊ±±ªºÃþ§O·|¨Ì¾Ú¬O§_¤wÃѧO¥X¾Ö¦³¼ç¦bÃzµo¦M¾÷ªº¬y·P¯f¬r¦b¹}¾i°Êª«¡B³¥¥Í°Êª«©Î¤HÃþ¨­¤W¡AÁÙ¦³¯f¬rªº¤wª¾©Î¹w´Áªº¦a²z¬y³q¦ì¸m(WHO 2005e)¡C

¯f¬rºÊ±±·|¤Þ»â¬ÛÃö±¹¬I¡A¦b³]©wºÊ±±ªºÀu¥ý¦¸§Ç¤§«e¡A¦U°ê­º¥ý­n©w¤UºÊ±±ªº¥Ø¼Ð¡C¹êÅç«Çªº½TÃÒ³t«×·|¼vÅT±±¨î´ú¶q§¹¦¨ªº³t«×¡C¥@½Ã±j¯P«Øij­n¤À¶}¤ÀªR¦³¼ç¦bÃzµo¦M¾÷ªº¬y·P¯f¬r©M¤@¯ë¨Ò¦æªº¬y·P¶EÂ_¡C

°ê¤º©M°ê»Úªº³ø§i¨t²ÎÀ³¦Ò¼{¨ì³Ì·sªº°ê»Ú°·±d³W³¹(IHR 2005)¡C

¦b¨â¦¸Ãzµo¤§¶¡ªº¶g´Á»PÃzµoĵ§Ù¶g´Á´Á¶¡(²Ä¤@¦Ü²Ä¤­´Á)¡A©Ò¦³°ê®aªº¯f¬rºÊ±±À³§Ö³t¿ë§O¬y³q¯f¬rªº«~ºØ¬°¥Ø¼Ð¡AºÉ¦­µo²{©M³ø§i¦b°Êª«©M¤HÃþ¶¡ªº¼ç¦bÃzµo¦M¾÷¡C¨üÃzµo¦M¾÷©Ò¼vÅTªº°ê®aÀ³½T©wÃzµo¦ì¸mªº¤À§G©M¤H¶Ç¤Hªº®Ä²v¡C¦b³o¬q´Á¶¡ªº¦æ°Ê¬O: ¹êÅç«Ç¯f¬rºÊ±±¡Bªù¶E³ø§i¨t²Î¥]¬AÂå°|³ø§i¡B¤@¸s¤H±w«æ©Ê©I§l¨t²Î¯e¯fªº¹w¥ýĵ§i¨t²Î¡B°ò¥»°Êª«ºÊ±±¨t²Î©M¦@¦P°Ñ·ÓÃѧO«D¨å«¬¬y·Pªº¹êÅç¤èªk¡C¨ü°Êª«Ãzµo¼vÅTªº°ê®a¨ä±¹¬IÀ³¥]¬A­Ó®×½Õ¬d¤Î±µÄ²°l¬d¡B±w¯f¸s½Õ¬d¤Î°ª¦M¤@±Úªº°·±dºÊ¹î¡C¦bÃzµo´Á«eªººÊ±±±¹¬IÀ³¥]¬AªÍª¢ºÊ±±©M¯f¬r§ÜÃĩʪººÊ´ú(WHO 2004)¡C

­«ÂIÀ³¥I¬y·PÃzµoªºÂå°|¬°¥»ºÊ´ú¹ï¤Î®Éµo°_ªº¤½²³°·±d±¹¬I©M¹êÅç«Ç¬ã¨s¦³¨M©w©Êªº§@¥Î¡C¥þ°ê©ÊªºÂå°|ºÊ´ú©Mĵ§Ùºôµ¸À³±q©Ò¦³ªºÂå°|¯f¤H¤¤¹îı­Ó§Oªº«æ©Ê©I§l¨t²Î¯e¯f©Î¦bªÀ°Ï¤¤ªº¸sÅé©ÊÄY­««æ©Ê©I§l¨t²Î¯e¯f¡C­«ÂIÀ³¥I¬y·PÃzµoªºÂåÅ@¤H­ûÀ³±µ¨ü¯S©w°V½m¥HÀ³¥I¤j«¬¬y·PÃzµo¡C¹ï©ó¤@¯ëÂåÅ@¤H­û¡B¹êÅç«Ç¤u§@¤H­û¡B¸q¤u©M·|À°§UÀ³¥I¬Ì¯g¦ý¤´¥¼¦³¨¬°÷¯à¤Oªº¤Hªº±Ð¨|©M°V½m¤]À³¬O¦Ò¼{¶µ¥Ø¤§¤@¡C

 

¼i¦æ¹êÅç¶E¯gªA°È

®Ú¾Ú¥@½Ãªº·§­z(WHO 2005e)¡A°ò¥»ªº¶E¯g®e¶q¤@©w­n¨¬°÷µ¹§Ö³tÀË©w¤HÃþºÃ¦ü¬y·P·P¬V­Ó®×¡C¦b¸ê·½¦³­­ªº°ê®a¤¤¡A¦³¦Û¤v±Mªø(¨Ò¦p¬y·P¶EÂ_)ªº¹êÅç«ÇÀ³«Ø¥ßÁpºô¡C¦b¨â¦¸Ãzµo¤§¶¡ªº¶g´Á¡A©Ò¦³°ê®aÀ³¨Ï¥Î³Ì¤p¤@­Ó¹êÅç«Ç¨Óµ¹¤©¨Ò¦æ¬y·P¶EÂ_©M¤ÀÃþ¡A¦ý¤£»Ý¯f¬r«~ºØŲ©w¡A¦Ó³o¨Ç¹êÅç«ÇÀ³Åý¥@½Ãª¾¹Dªº¡C¹êÅç«Çªº³Ì¤pÀË´ú®e¶qÀ³¦³§ÜÅé¿Ã¥ú¬V¦â(IF)©M°fÂà¿ý?»E¦XÃì¤ÏÀ³(RT-PCR)¡C¦b¯Ê¥F³o¨Ç¯àµ¹¤©¨Ò¦æ¬y·P¶EÂ_©M¤ÀÃþªº¹êÅç«Çªº°ê®aÀ³¨Ï¥Î§Ö³t§Ü­ì´ú©w¤u¨ã¥]¡A¦ý¬O¬F©²À³¹º¥X¨ä¥L¸ê·½©Î±N³o¨Ç¬y·P¶EÂ_¦b¨ä¥L°ê®a¤¤°µ¥HÀx¦s¨¬°÷¸ê·½¨Ó«Ø¥ß¬y¦æ¯f¾ÇºÊ±±¹êÅç«Ç¡C

¦b³Ì²z·Qªº±ø¥ó¤U¡A°ê¤ºÀ³¦³ªþ¦³¹êÅç«Ç¦w¥þ(BSL)¤T¯Å¦Ü¥|¯Åªº¹êÅç«Ç¥Ø¿ý¡A¦ý¬Oµo®i¤¤°ê®a³q±`¨S¦³²Ä¥|¯Å¦w¥þªº¹êÅç«Ç©M¥u¬O¦³«Ü¤Ö©Î¨S¦³²Ä¤T¯Å¦w¥þªº¹êÅç«Ç¡A©Ò¥H¯à¨Ï¥Îªº¤T¯Å¦w¥þ¹êÅç«ÇÀ³µo®i¦¨§½³¡¤u§@(³o¼Ë¯à¥[§Ö¶EÂ_)©Î»P¨ä¥L°ê®a¥Ñ¥@½Ã«P¶iªº¤T¯Å©Î¥|¯Å¦w¥þ¹êÅç«Ç§@¬ù©w¡C¦b¬y·PÃzµoªº¦­´Á¡A·í¶EÂ_¬y·P¯f¼xªº¯f¤H¤£¯à®e©ö°²©w¬O¯uªº®É¡A´ú¸Õ«K»Ý­n¼W¥[¡C¤@¦ý¬Ì¯g¤wÃzµo¡A´ú¸Õ©Ò¦³­Ó®×¬O¤£¥i¯àªº¡A¹êÅç«ÇÀ³´£¨Ñ©w´Á©¾§iµ¹ÂåÅ@¤H­û¡C°ê®aªº¬Ì¯gÃzµo·Ç³Æ­p¹º¥]¬A§Ü¯f¬rÃĪº¨Ï¥Î¡A¹êÅç«ÇÀ³­t³dºÊ¹î¯f¬rªº§ÜÃÄ©Ê¡C¤é±`­Ó®×¡A¥]¬A·P¬Vªº¥i¯à¨Ó·½³ø§iÀ³¨C¤Ñ»¼¥æµ¹°ê®a¦³Ãö·í§½©M¥@½Ã(WHO 2005e)¡C

 

¬Ì­]

±±¨î¬y·P¯f¬r·P¬Vªº³Ì¦n¤èªk¬O§Ü¯f¬rªvÀø©M¬Ì­]±µºØ(Yen 2005, Korsman 2006)¡A¦Ó¬Ì­]±µºØ¬O«OÅ@ªº³Ì¦³®Ä¤èªk(van Dalen 2005)¡A¦ý¾A¦Xªº¬Ì­]¦b·sªº¯f¬r¯B²{¤§«e¬O¤£¥i¯à»s³yªº¡C¦b¤@¯ë±¡ªp¤U»Ý­n³Ì¤Ö¤»­Ó¤ëªº®É¶¡¥hµo®i¤Î¤j¶q¥Í²£(Flemming 2005)¡C§Y¨Ï¦p¦¹¡A¤j³¡¥÷°ê®a¤´¨S¦³¬Ì­]¥Í²£³]¬I¡A¦bÃzµoªº²Ä¤@ªi¨S¿ìªk¥h¥Í²£¬Ì­]¡A³o³y¦¨¥þ²y¬Ì­]¥Í²£¼Æ¶q¦³­­©M¥Í²£³]¬I¶°¤¤©ó¤wµo®i°ê®a¡C

¦b¬y·PÃzµo®É¡A¦³¬Ì­]¥Í²£³]¬Iªº°ê®aÀ³ºÉ¤O¤ä«ù©M½T«O§Ö³t¤Î¤j¶q¥Í²£¬Ì­]¡C¤@¨Ç¤wµo®i°ê®aªº¬F©²µø¬Ì­]¥Í²£¥H´£¨Ñ¦bÃzµoªì´Á³Ì°ªªº«OÅ@¬°¦Û¤vªº³d¥ô¡A¨Ò¦p²üÄõ¬F©²¥¿»P¥Í²£°Ó½Í§P¥h½T«O±N¨Óªº¥ô¦ó¬y·PÃzµo³£¦³¨¬°÷ªº¬y·P¬Ì­]¨Ñµ¹²üÄõ(van Dalen 2005)¡C¨S¦³¬Ì­]¥Í²£³]¬Iªº°ê®aÀ³ºÉ§Ö·Ç³Æ¬Ì­]±µºØ­p¹º¡A·í¬Ì­]¯à´£¨Ñ®É«K¯à¹ê¬I©è§Ü¬Ì¯g( WHO 2005e)¡C

¬Ì­]±µºØ­p¹ºÀ³¥]¬A: ¥ô©R¤j²³§K¬Ì¶E©Ò¡B¤H­û°t³Æµ¦²¤¤Î°V½m¡B®Ú¾Ú¥ý«á¦¸§Ç§@¦³­­¤À°tµ¦²¤¡B´H§N¦a°Ïªº¬Ì­]Àx¦s¶q¡BÃѧO²{®É©Î¼ç¦bªºÀ³«æ­Ü®w¡B¹B¿é®Éªº¬Ì­]«O¦w(¨¾¤îµsÅÑ)¡B¦b¶E©ÒªºÀx¦s©M¨Ï¥Î¡CÀu¥ý¨Ï¥Îªº¤H¤h¨Ò¦p°â½æ°Êª«©M¸V³¾ªº¤H¤h¡B¹A¥Á¡BÂåÅ@¤H­û©M¨ä¥L¦³Ãö¤H¤h(WHO 2005e)¡C

 

§Ü¯f¬rÃĪ«

§Ü¯f¬rÃĪ«¥]¬AM2§í¨î¾¯¡A³o¬Oªý¶ëÂ÷¤l³q¹D¾¯(ª÷­èÓi[amantadine]©Mª÷­è¤AÓi[rimantadine])©M¯«¸g®ò»ÄžJ§í¨î¾¯(¶ø´µ¥L°¶[oseltamivir]©M¤ã¨º¦Ì­³[zanamivir]) (Hoffmann 2006b)¡C¨Ï¥Î¥ô¦ó§Ü¯f¬rÃĪ«®É¡A¯f¬rªº§ÜÃĩʬO­È±oÃöª`ªº¡C¨Ï¥ÎM2§í¨î¾¯§@ªvÀø·|¾É­P³Ì¤Ö30%¤H¦³§¹¥þ­P¯f©Ê©M¶Ç¬V©Êªº§ÜÃĩʯf¬r(Hayden 1997)¡AÁÙ¦³M2§í¨î¾¯¹ï§ÜH5N1ªº¬¡Åé¥~´ú¸Õ¤£¬O«Ü¦³®Ä(Lipatov 2004)¡C

¨Ï¥Î¯«¸g®ò»Ä?§í¨î¾¯§@ªvÀø·|¾É­P¤j¬ù4¦Ü8%¤p«Ä©M¤Ö¹L1%¦¨¤H¦³§ÜÃĩʯf¬r(McKimm-Breschkin 2003, Stilianakis 2002)¡A¨ä«áÃÒ¹ê18%ªº¤é¥»¤p«Ä¨Ï¥Î¶ø´µ¥L°¶ªvÀø«á¦³§ÜÃĩʯf¬r(Kiso 2004)¡C³Ìªñ¦³¨â¦W¶V«n¯f¤H¨Ï¥Î¶ø´µ¥L°¶ªvÀø«á¥X²{§ÜÃÄ©Ê¥Ò«¬¬y·P(H5N1)¯f¬r(de Jong 2005)¡A§óµo²{¥L­Ì¨­¤Wªº¥Ò«¬¬y·P(H5N1)¯f¬rªºH274Y¯«¸g®ò»ÄžJ°ò¦]¹ï¶ø´µ¥L°¶¦³°ª«×ªº©è§Ü©Ê(Gubareva 2001)¡CÁöµM­ã³\¨Ï¥Î¶ø´µ¥L°¶¦b«Øijªº¾¯¶q©MÀøµ{(¨C¤é¨â¦¸¡A¨C¦¸75²@¤É¡A³sÄòªA¥Î¤­¤é¡A¤£¨¬13·³ªº¨àµ£­n±N¾¯¶q´î¤Ö)¡A­Ý¥B­n¶}©lÀøµ{¦b³Ì¤jªºÁ{§É®Ä¯q¤W(¯f¼x¥X²{ªº48¤p®É¤º)¡A³o¨â¦W¯f¤H³Ì²×³£¦º¤`¡A³oÅã¥Ü§ÜÃĩʾɭPªvÀø¥¢®Ä¡C§@ªÌ±ÀÂ_¥¼¨Óªºµ¦²¤­«ÂI¦b©ó´£°ª§Ü¯f¬r®Ä²v(¨Ò¦p°ª¾¯¶qªº¨Ï¥Î¡Bªø®É´ÁªºªvÀø©Mµ²¦X¦¡ªvÀø)¡C

·sªºµ¹¤_§Ü¯f¬rªº¤èªkÀ³¤£Â_±´¯Á¡A¦]ÄY­«¬y·P¯f¤H¤w¦³§ïÅܤFÃIJz°Ê¤O¾Çªº°ÝÃD¡A©Ò¥H·|µo¥Í¸¡Âm(Hien 2004)¡C

¤p«Ä©M´¼»Ù©Î¥¢½Õ¯f¤H¤£¯à«ê·í¦a§l¤J¤ã¨º¦Ì­³¬O­È±oÃöª`ªº(Imuta 2003)¡A¦ý¬O²{®Éªº«Øij¥ÎÃĨ϶ø´µ¥L°¶§ÜÃĩʪº¥X²{©M¤ã¨º¦Ì­³¥i¯à¶É¦V¤Ö¨Ç¥X²{§ÜÃÄ©Ê(Moscona 2005)¡A¤ã¨º¦Ì­³À³¥]¬A¦bªvÀø¥Ò«¬¬y·P(H5N1)¯f¬r·P¬VªºªZ¾¹¤§¤@ºØ¡C

 

ÃĪ«Àx¦s

¦³¨Ç¬F©²³Ìªñ¿ï¾ÜÀx¦s¶ø´µ¥L°¶¡A¨C­Ó°ê®aªºÀx¦s¤è°wÀ³®Ú¾Ú²{¦s¸ê·½©M¤H¤f¦Ó©w¡C¥@½Ã·¥¤O¥D±i¦U°ê¨Æ¥ýÀx¦s¨¬°÷ÃĪ«(Abbott 2005)¡A¨Ò¦p²üÄõ¬F©²¤wÀx¦s¤j¬ù225000¶ø´µ¥L°¶¨t¦C(Groeneveld 2005)¡A¦ý¬O«Ü¦hµo®i¤¤°ê®a¤£¯à­t¾áÀx¦s§Ü¯f¬rÃĪ«ªº¸g¶O¡C

Àx¦sÃĪ«ªº¦n³B©M³Ì¨Îªº§Ü¯f¬rÃĪ«¨Ï¥Îµ¦²¤³Ìªñ¥Î¥H¦â¦C¤H¥H«eÃzµoªº¸ê®Æ(¯f¤H¼Æ¥Ø¡BÂå¥Í¨Ó³X¡B¦í°|¤H¼Æ©M¦º¤`¼Æ¦r)½Õ¬d¡C­pºâÂåÀø¨t²Îªº¥N»ù©M¸gÀÙ¤WªºÁ`¥N»ù¡A«áªÌ¥]¬A·l¥¢¤u§@¤Ñªº»ù­È¦Ó¤£¬O¼ç¦b¤H©Rªº·l¥¢(Balicer 2005)¡C¤T­Ó¦bÃzµo¨ä¶¡¨Ï¥Î¶ø´µ¥L°¶ªºµ¦²¤©w¬°: ªvÀø¤Wªº¨Ï¥Î¡Bªø´ÁÃzµo«eªº¹w¨¾©Mµu´ÁÃzµo«áªº¹w¨¾µ¹ºò±K±µÄ²¬y·P¯f¤Hªº¤H¤h(¦bªvÀø³Q¼Ð»xªº¯f¤H)¡CÀY¨â­Óµ¦²¤ªº¥Ø¼Ð¥i¥H¬O¥þ¤H¤f©Î¥u¬O¦³°ª­·ÀI¥X²{¨Öµo¯gªº¤H¤h¡C¨C­Óµ¦²¤ªº¸gÀÙµ²ªG³£·|¤£¤z¹w¦a¤ñ¸û¡AÀx¦s¦¨¥»ªº¦ô­p©M¦¨¥»®Ä¯q¤ñ¨Òªº­pºâ¡A³Ì¨Îªº¦¨¥»®Ä¯q¤ñ¨Ò¥X²{¦bÀx¦s§Ü¯f¬rÃĪ«¥u§@ªvÀø©Î§@µu´Áªº¹w¨¾¡C¦³¤@ºØµ¦²¤¦W¥s"¥Ø¼Ð¹w¨¾"(Longini 2004)¡A¨ä¥Ø¼Ð¬O¥Î³Ì¤pªºÃÄ¥H´«¨ú³Ì¤jªº®ÄªG¡A©Ò¥H¥Ø¼Ð¹w¨¾¦bµo®i¤¤°ê®a¹ï¸`¬Ù¸ê·½«Ü­«­n¡C

¦b¤j³¡¥÷ªºµo®i¤¤°ê®a¨Ï¥Î§Ü¯f¬rÃĪ«¬O¥¼¹w®Æ¨ìªº¡A¦b¤wµo®i°ê®a¨Ï¥Î§Ü¯f¬rÃĪ«®Ú¾ÚÃĪ«¬O­­¶qÁÙ¬O¤j¶q¨ÑÀ³(¬Ýªí¤T)¡C

 

ªí3. ²üÄõ½Ã¥Í§½«Øij¨Ï¥Î§Ü¯f¬rÃĪ««ü¤Þ(¥X¦ÛGroeneveld 2005)
1. ·íÃzµo¤w¨ì¹F²üÄõ
 

ºØÃþ

¼Ð»x¯f¤Ha

´£¨Ñ¹w¨¾µ¹

®a®x¡B¦P«Î¦í¤á©M¨ä¥L©M³Q¼Ð»x¯f¤H¦³±µÄ²ªº¤H: ¼ÉÅS«áªº¹w¨¾

2. Ãzµo¤wÀH³B¥i¨£©Î¦³¤j³W¼Ò¯f¬r±q¥~¦a¶Ç¨Ó
¦pªG¯«¸g®ò»ÄžJ§í¨î¾¯ªº¨ÑÀ³¯Ê¥F

ºØÃþ

¦M¾÷¸sb¡B±M·~¤H¤hc¡B©M(·í¬ÛÃö®É)¦bÃzµo¤¤¯S©wªº¦M¾÷¸sa; °£¦¹¤§¥~ªº¥¿±`¤H: ¦]¨Öµo¯g¦Ó»Ý­n¦í°|

 
¦pªG¯«¸g®ò»ÄžJ§í¨î¾¯ªº¨ÑÀ³¥R¨¬

ºØÃþ

¯f¤H¥X²{¯f¼x»P¬y·P¬Û¦ü

´£¨Ñ¹w¨¾µ¹

­Ó§O¯f¤Hd ©M¦M¾÷¸s¡B ±M·~¤H¤h©M(·í¬ÛÃö®É)¦bÃzµo¤¤¯S©wªº¦M¾÷¸se

a. ºÉ§Ö¶}©lªvÀø¦b¯f¼x¥X²{®É¡A¦pªG¤£¦b48¤p®É¤º¶}©l¡A®ÄªG·|­°§C¡C
b. ¦³ÄY­«©I§l¨t²Î¡BªÍ³¡©Î¤ß¦åºÞ¤£¥¿±`©M©x¯à»Ùꪺ¯f¤H­YªG·P¬V¬y·P¯f¬r«K«Ü¦³´X·| ¾É­PªÍ³¡©Î¤ß¦åºÞ¥\¯à°I°h©M¿}§¿¯f¡C
c. ©Ò¦³­t³d¶EÂ_¡BªvÀø©M·ÓÅU¬y·P¯f¤H©Î¥²­n¸ê·½ªºª«¬yºÞ²z¤H­û¡C
d. ·í¦³³d¥ô¥hºÊ¹î­Ó§O¯f¤HªºÂå¥Í»{¬°¾A¦X®É¡C
e. ¯f¬r¬y³q®É¤Î¬Ì­]±µºØ¤§«á¡C

­Ó¤HÀx¦s¶ø´µ¥L°¶¬O·¥¤£«Øijªº(Brett 2005, Moscona 2005)¡A¦]¬°·|¾É­P¨Ï¥Îªº¾¯¶q¤£°÷©Î¤£¾A·íªvÀø¡AÁÙ·|«P¨Ï§Ü¶ø´µ¥L°¶¯f¬rªº¥X²{¡C¦¹¥~¡A­Ó¤HÀx¦s¶ø´µ¥L°¶§ó·|¯ÓºÉ¥«­±¤W¦­¤w¨Ñ¤£À³¨Dªº¸ê·½¡C

¨C¶¡Âå°|À³Àx¦s¬°ªvÀøª÷¶À¸²µå²yµß©M¨ä¥L¶¡±µ·P¬Vªº§Ü¥Í¯À¡C

 

¤@¯ë±¹¬I

«DÂå¾Ç¤z¹w©M±±¨î¶Ç¬V©Ê¯e¯fªº¥X²{¦³±K¤ÁÃö«Y¡C¦b®õ°ê¡A¤£¦P¼h­±ªºªÀ°Ï°Ñ»P³Qµø¬°°ê¤º©è§ÜH5N1¸V¬y·Pªº­p¹º¡C¤½²³°·±d¤u§@ªÌ¡B°Êª«°·±d¤u§@ªÌ¡B§ø²ø°·±d¸q¤u©M¨ä¥L°Ñ»PªÌ¦b2004¦~10¤ë¶}©l«K¤£¶¡Â_¦a¨Ì·Ó°ê®a¦³Ãö·í§½©Òµo¥Xªº«ü¤Þ¥H°Ñ¥[¬Ì±¡ºÊ±±¹B°Ê¥[¤W (Barnett 2005)¡C¦b®õ°ê¡A2004¦~¦³17¦W¯f¤H·P¬VH5N1¡A¦ý¥h¦~¥u¦³5¦W¯f¤H·P¬V¡A³oÅã¥Ü°ê¤º©è§ÜH5N1¸V¬y·Pªº­p¹º¨ú±oªì¨B¦¨¥\(WHO 2005c)¡C¤£¦P³¡ªùªº¨ó½Õ¥]¬A«D½Ã¥Í³¡ªù(¤×¨ä¬O¹A·~¡B¸gÀÙ¡BªÀ·|©M¤º°È)¬O»Ý­nªº¡A½Ã¥Í³¡ªù¥H¥~ªº±M·~ºôµ¸(ªk«ß¡B±Ð¨|©M®È¹C·~)¤]À³±q¨Æ©ó­p¹º¤u§@¡C

¦³®Äªº¨Æ«e­·ÀI³q°T¥i´î§C¨Æµo®Éªº³q°T»Ùê(USDHHS 2005)¡A¨Æ«e­·ÀI³q°Tµ¹¦b¦M¾÷¤¤¤@±Ú©M´¶Ã¹¤j²³³Ì¯à´î§CªÀ·|ºò±i¡C³q¹L¶Ç´C¡A¤j²³¯à±o¨ì¥²­nªº¸ê®Æ¦n¹³¬ÛÃö½Ã¥Í±¹¬I¡B¨¾¿m¤èªk¡B¤£«Øijªº¬¡°Ê¡B¦M¾÷½m²ß©M¨ä¥L¬ÛÃö°ÝÃD¡C¶Ç´C¥çÀ³¶Ç¼½¬y·Pªº´¶³qª¾ÃѤÎÃzµoªº«Â¯Ù¥H¤Þ°_¤½²³Ãöª`¡C

±M·~«O°·ªº°V½m¦æ°Ê¯S§O¦aÀ³¥Î¦b¤j³W¼ÒÃzµoªº·Ç³Æ¡A³o¹ï¼W¥[«O°·¤u¤Hªº­Ó¤H«OÅ@¸Ë³Æ©M¶Ç¬V±±¨îµ{§Çªº©Ó¿Õ«Ü¦³À°§U¡C

³Ì«á¡AÃzµo¼ÒÀÀ¹ê²ß¹ï¾Ç²ßÀ³¦bÃzµoµo¥Í®É°µ¤°»ò«Ü¦³À°§U¡C¤j¬ù¤@¤d¦W«O°·¤u¤H©M¥«¥Á°Ñ»P¦b¶V«n­º³£ªe¤º¶i¦æ¤F¤@¦¸ªººò«æºt²ß¡A³oºt²ß¯àÁëÁå©x¤è¹ï¸V¬y·PÃzµoªº¤ÏÀ³¡C¬O¦¸ºt²ß¬O¥Ñ¥«¤º¾÷Ãö¦w±Æ¡A°Ñ»PªÌ¦³¥»¦a¤H¥Á¡BÂå°|¡B«O¦w©Mªe¤ºªøÀذϪº­x¶¤(Thanhnien 2005)¡C

 

¶g´Á©Êªº¬y·P¬Ì­]±µºØ

ºD±`ªº¬y·P¬Ì­]À³±µºØ¦b¦M¾÷¤@±Ú¨­¤W¥h´î§C­«ÂзP¬V¶g´Á©Ê¬y³q¬y·P¯f¬r©M¼ç¦bÃzµo¯f¬rªº¾÷·|¡A¦]¬°³o¼Ë°µ·|´î¤Ö¯f¬rªº­«°tªº¾÷·|¡C·À¬¡¬y·P¯f¬r¬Ì­]«Øij¨Ï¥Î¦b¥H¤U¸û°ª­·ÀI¥X²{¨Öµo¯gªº¤H¤h(ACIP 2005):

  • ¦~ÄÖ¤j©ó¤»¤Q¤­·³
  • Àø¾i°|ªº©~¥Á©M¨ä¥L´£¨Ñªø´Á·ÓÅUªº³]¬Iªº¥ô¦ó¦~ÄÖªø´Á¨üÂåÀø·ÓÅUªÌ
  • ¦³ªø´ÁªÍ¯f©Î¤ß¦åºÞ¨t²Î¯e¯f¥]¬A­ý³Ý(°ª¦åÀ£¤£³Qµø¬°°ª­·ÀI)ªº¦¨¤H©M¤p«Ä
  • ¦b¥h¦~¦]ºC©Ê·s³¯¥NÁ¯e¯f(¥]¬A¿}§¿¯f)¡BµÇ°IºÜ¡B¦å¬õ¯À¯fÅܱwªÌ¡B§K¬Ì¤O§í¨î(¥]¬AÃÄÀøªk©Î¤HÃþ§K¬Ì¯Ê¥F¯g¯f¬r[HIV]©Ò¤Þ°_ªº)¦Ó»Ý­n©w´ÁÂå¾Ç¸ò¶i©Î¦í°|ªº¦¨¤H©M¤p«Ä
  • ¦³¥i¦M¤Î©I§l¨t²Î¥\¯à©Î©I§l¹D¤Àªcª«¡A§Y¬O¯à¼W¥[¯f¬r§l¤J­·ÀIªº±¡ªpªº¦¨¤H©M¤p«Ä(¨Ò¦p»{ª¾»Ùê¡B¯á´Õ¯«¸g¨ü·l¡B«æ©Êµo§@¯f©M¨ä¥L¯«¸g¦Ù¦×¥¢½Õ)
  • ¤p«Ä©M«C¤Ö¦~(¤»­Ó¤ë¤j¦Ü¤Q¤K·³)ªø´Á¨Ï¥Îªü¤h¤ÇÆFªÌ¥i¯à¦]·P¬V¬y·P¦Ó¥X²{¹p¤ó¯g­Ô¸s
  • ¬y·P©u¸`ªº¥¥°ü
  • ¤»¦Ü¤G¤Q¤T­Ó¤ë¤jªº¤p«Ä

 

¬Fªv©Ó¿Õ

¤@­Ó³Ì­«­nªº¦]¯À¬O¬Fªv©MªÀ·|¹ï§iª¾©M³ø§i¬Ì±¡´²¼½ªº¦ÛÄ@©Ê¡A¨S¦³³o­Ó­«­n¦]¯À¡A¶i¤@¨Bªý¤î¬Ì±¡Ãzµoªº°ê¤º¦æ°Ê«KµLªk¹ê¦æ¡C°ª«×ªº¬Fªv¤ä´©©M©Ó¿Õ¹ïµo®i·Ç³Æ­p¹º¬O¥²»Ýªº¡A¼W¥[°Ï°ì¦X§@©M«Ø¥ßÁpôºôµ¸¤£³æ¯à¨Ï¦b¨î©w­p¹º®É¬Û¤¬¤ä´©¡A§ó¥i§@¬°¼W¥[°ê»ÚÀ£¤O©M¬Fªv©Ó¿Õªº¤u¨ã(WHO 2004)¡C±q¹L©¹Ãzµo°O¿ý¡A¤×¨ä¬O1918¦~¨º¦¸¡AÅã¥Ü¥X¬Ì¯gÃzµo¹ï¥ô¤@°ê®a¦]¹ï°ê¤ºªºªÀ·|¸gÀÙ©M¬FªvÅé¨tªº½ÄÀ»·|¦³¨aÃø©Êªº«áªG(PPHSN 2004)¡C

 

ªk«ß©M¹D¼w°ÝÃD

¾A·í¥ßªkÀ³¦b¬Ì¯g¨ÓÁ{«e¤w°µ¦n¡C¤@­Ó¥þ°ê©Ê¨aÃø¡G¨Ò¦p¬Ì¯gÃzµo¡A¥²»Ý¦³¤@­Ó¥ßªk¨î«×¤ä«ù¤~¥i¦³®Ä¦a¼i¦æ¨º¸Ìªº¤½²³°·±d±¹¬I¡A¨Ò¦p¹ê¬I¹jÂ÷³q±`»Ý­n¨üÅv§å­ã©M±Ä¨ú¥²­n±¹¬I¥h§ùµ´©M±±¨î¯e¯fªº´²¼½(PPHSN 2004)¡C¦pªG¬Ì­]±µºØ¬O¹K¤î¬Ì¯gÃzµoªº¥²­n±¹¬I¡A¨º»ò«K»Ý­n¤@­Ó¦P¼Ëªº°ªÀ£±¹¬I¡C

 

¸êª÷Äw¶°

¸ê·½¦³­­ªº°ê®a»Ý®Ú¾Ú²{¦sªº¸ê·½©M¤H¤fªº¤j¤p»Pµ²ºc¥h³W¹º¤@­Ó¥i¦æªº¥þ°ê©Ê¬y·PÃzµo·Ç³Æ­p¹º¡C°ª«×¬Fªv¤ä´©¹ï¸êª÷¤À°tµ¹ºò«æ±¡ªp¦n¹³¬y·PÃzµo¬O³Ì­«­nªº¡A­p¹º¹Lµ{À³¥]¬A½T»{¥i¥Î¸ê·½¥H´£¨ÑÃzµo®É¬ÛÀ³ªº¸êª÷¡C

 

³vº¥±±¨î°ª­P¯f©Ê¸V¬y·Pªº¥þ²yµ¦²¤

°ª­P¯f©Ê¸V¬y·P(HPAI)³vº¥´²¼½¨ì·s¦a°Ï»Ý­n»P¨ä¥L¦³¦M¾÷ªº°ê®a¦³¬¡ÅDªº¥æ¬y¡A¯S§O¬O¦³­Ô³¾¾E±p¸ô½uªº°ê®a¡A»Ý­n¼W¥[ºÊ±±¡B±´¹î¯à¤O©Mºò«æ·Ç³Æ¡C¤½²³Ãöª`¥[¤W¹ï±M·~Ã~Âå¡B¹A¥Á¡B¥«³õ°Ó¤H¡B¸V³¾¹B¿é©Ó¿ì°Ó©M±Ä³JªÌªº±Ð¨|»P°ö°V¥h½T«O¯e¯f¬O¤w³Q¨î¤î¤F©Î¬O¤w³Q¹îı©M±±¨î¡A¥H¨¾¤î¬Ì¯f¥i¥H¦b¥t¤@­Ó·sªº¥ÍºA¨t²Î«Ø¥ß©Mºû«ù (FAO 2005)¡C

Áp¦X°ê³­¹¤Î¹A·~²Õ´(FAO)©M¥@¬É°Êª«½Ã¥Í²Õ´(OIE)»P¥@½Ã¦X§@¶}©lµo®i¥þ²y³v¨B±±¨î©M®ø·ÀHPAIµ¦²¤¡A³oµ¦²¤ªºÁ`¥Ø¼Ð¬O³Ì²×¯à±q¨È¬w©M¼Ú¬w°Ïªº®a¸V®ø·ÀHPAI©M¨¾¤îHPAI¶i¤@¨B¶Ç¤J¨ä¥L¥¼³Q·P¬Vªº°ê®a¡A¨º«K¯à´î§C¬Ì¯f¦b¤HÃþÃzµoªº¥þ²y¦M¾÷¡B«P¶i¥i¹ê¦æªº®a¸V¥Í²£¡B´£°ª¥»¦a©M°ê»Ú®a¸V©M®a¸V²£«~¶T©öªºÃ­©T©Ê¡B¼W¥[­¹ª«©M¹}®Æªº¦w¥þ©M¹}¾i®a¸V¬°¥Íªº¤Hªº¥Í­p¡A¤×¨ä¬O¶m­¥³h§xªº¤H(FAO, OIE, WHO 2005)¡C

±±¨î°ª­P¯f©Ê¸V¬y·P¦³´XºØ¤èªk: 1) ¨Ï¥Î¤w±»»\ªº®a¸V«Î©M¤w³B²z¹Lªº¤ô¨¾¤î³¥¥Í©M¹}¾iªº¸V³¾±µÄ²; 2) ¨Ï¥Î¤w±»»\ªº®a¸V«Î©M¤w³B²z¹Lªº¤ô©M¸T¤î¤ô¸V¦b"Àã³f¥«³õ"¥X²{¥H¨¾¤î¤ô¸V©MÂû°¦±µÄ²; 3) ¨Ï¥Î¿ï¾Üªk©Î¬Ì­]ª`®g¥h¨¾¤î¯e¯f¶Ç¼½¥H®ø°£Âû°¦¨­¤WH5/H7¬y·P¯f¬r; 4) ¨¾¤î©Î´î§C®a¸V¡B½Þ°¦©M¤HÃþ¤¬¬Û±µÄ²©M¨Ï¬Ì­]©M§Ü¯f¬rÃĪ«ªº¨ÑÀ³¤£µ´(Webster 2006)¡C

 

Ãzµo¶g´Á

¦bÃzµo¶g´Á´Á¶¡¡A¥D­n¥Ø¼Ð¬O«ÊÂê¬Fµ¦¡C¤§«e¤w»¡¹L±±¨î¬Ì±¡¦¨¥\¦b©ó¦­´ÁŲ©w²Ä¤@§åÃzµo¸s(Ferguson 2004)©M¹îı°ª¤ñ²v¤£Â_¤W¤Éªº­Ó®×(Ferguson 2005)¡A©Ò¥H¦b³o¼Ë³Ì¨ÎªººÊ±±¬O¦¨¥\«ÊÂê©Ò¥²³Æªº¡C

 

¬Ì±¡ºÊ±±

¬Ì±¡ºÊ±±À³¥]¬AºÊ¹î¥H¤U¨Æ¶µ: Âå°|¤J¦íªººÃ¦ü©ÎÃÒ¹ê¬y·P­Ó®×¡B¦]ºÃ¦ü©ÎÃÒ¹ê¬y·P¦Ó¦º¤`ªº­Ó®×¡B¥²­nªA°Èªº³Ò¤u¯Ê¥F²v¡B¤@¯ë©M¤j³W¼ÒÃzµoªº¬y·P¬Ì­]¨Ï¥Î(¦pªG¯à´£¨Ñ¬Ì­])¡B¤j³W¼ÒÃzµoªº¬y·P¬Ì­]ªº°Æ§@¥Î(¦pªG¦³)¡B¼Æ¾Ú¦¬¶°¥H§@¬°¤é«á­pºâ¤j³W¼ÒÃzµoªº¬y·P¬Ì­]ªº®Ä²v¡BºÊ¹îªÍª¢Âù²yµß¬Ì­]ªº¨Ï¥Î»P°Æ§@¥Î(¦pªG¬Ì­]¤w¬O¥i¥Î©M¤w³Q¨Ï¥Î)©MºÊ¹î§Ü¯f¬rÃĪ«ªº¨Ï¥Î(¦p¤w¨Ï¥Î)»P¨ä°Æ§@¥Î¡AÁÙ¦³¤U¨M©w®É©Ò¥Î¨ìªº¼Æ¾Ú¶°¦¨¡B¤ÀªR©M¶Ç°eªº¾÷¨î¤@©w­nªÖ©w¡C¨C¤éªº­Ó®×³ø§i§eµ¹°ê®a¦³Ãö·í§½©M¥@½Ã¡A¨Ã¥²­n¥]¬A¥i¯àªº·P¬V·½ÀY¸ê®Æ(WHO 2005e)¡C

 

ªvÀø»PÂå°|¦¬®e

¦b·P¬V¤H¼ÆÁÙ¬O¤pªº®É­Ô¡AºÃ¦ü©ÎÃÒ¹ê±w¥Ò«¬¬y·P(H5N1)ªº¯f¤HÀ³¦bÂå°|±µ¨ü¹jÂ÷¶Eªv¥]¬AÁ{§ÉÆ[¹î¡B¾A·íªº¶EÂ_´ú¸Õ©M§Ü¯f¬rªvÀø¡A¯f¤H¤Î¨ä®aÄÝ­n±µ¨ü­Ó¤H½Ã¥Í±Ð¨|©M·P¬V±±¨î¤èªk¡C³B²z¤âªk¬O°ò©ó¤ä´©¬ÝÅ@¥[¤W®ñ®ðªº¨ÑÀ³©M³q­·¤ä´©¡CºÃ¦ü±w¥Ò«¬¬y·P(H5N1)ªº¯f¤HÀ³±µ¨ü¯«¸g®ò»ÄžJ§í¨î¾¯ª½¦Ü¦³¹êÅç«Ç¶EÂ_´ú¸Õªºµ²ªG(WCWHO 2005)¡C¸Ô±¡½Ð¬ÝHoffmann 2006

 

¤HÃþ¸ê·½: ­Ó¤H«O°·

«O°·¤u¤H±µÄ²¯f¤H®É«Øij¨Ï¥Î°ª®Ä²v¤f¸n(³QNIOSH«OÃÒªºN95©Î¦Pµ¥¤f¸n)¡Bªø³S³T¡B­±¸n©ÎÅ@¥ØÃè©M¤â®M¡C¦b¥i¯àªº±¡ªp¤U¡Aª½±µ±µÄ²¯f¤H©M¯f¤H¶gÃ䪺Àô¹Òªº«O°·¤u¤H¼Æ¥ØÀ³¨ü¨ì­­¨î¡A¯A¤Î°ª¦M¨BÆJ(¨Ò¦p®ð·»½¦»s³y)ªº«O°·¤u¤HÀ³¦Ò¼{§@¼ÉÅS«eªº¹w¨¾ªk(WCWHO 2005)¡C

 

¥Ø¼Ð¦a²z¹w¨¾ªk©MªÀ°Ï²¨»·ªk

¥i¥H¥Î¼Ò«¬¨Ó¦ô­p¬y·P¦³ÃöÁpªºµo¯f²v©M¦º¤`²v¡A§Y¨Ï²{¦æ¦b¤wµo®i°ê®a©Ò¨Ï¥Îªº¼Ò«¬¥i¯à¦bµo®i¤¤°ê®a¨Ã¤£¾A¥Î¡A¦ý¬Y¨Ç¦³½ìªº­ì²z¤´¬O­È±oµo®i¤¤°ê®aÃöª`¡C

±qªF«n¨È¬y·Pªº¼ÒÀÀ¶Ç¼½¼Ò«¬¨Ó¬Ý¡A¦pªG·s¯f¬rªº°ò¥»Ác´Þ¼Æ¤p©ó1.8¡Aµ²¦X¥Ø¼Ð¦a²z¹w¨¾ªk©MªÀ°Ï²¨»·ªk«K¥i¯à®ø°£¦­´Á¬y·P¤j³W¼ÒÃzµo(Ferguson 2005)¡C°ò¥»Ác´Þ¼ÆRo(Anderson 1992)¶q¤Æ¥ô¦ó¯f­ìÅ骺¶Ç¼½¯à¤O¡A©w¸q¬°¦b¨ü¼vÅTªº¤H¤f¤¤±q³Ìªìªº­Ó®×¤Þµo¥Xªº¤G¦¸­Ó®×ªº¥­§¡¼Æ¡C¤@­Ó¯e¯f¯à¶Ç¼½¶}¥h¦pªGRo>1¡A¦ý¦pªGRo<1¡A¶Ç¼½Ãì«K·|³vº¥®ø¥¢¡A©Ò¥H±±¨î¬Fµ¦ªº¥Ø¼Ð¬O±NRo´î¦Ü¤Ö©ó1¡C¦ý¬O±q³o­Ó¼ÒÀÀ¼Ò«¬¡AFerguson±ÀÂ_°ª¦¨¥\¾÷·|²v»Ý²Å¦X´X­Ó­«­n­ì«h: (1) §Ö³tÂ_©w²Ä¤@§å·P¬V¸s¡A(2) §Ö³t¤ÎÆF±Óªº­Ó®×§PÂ_©Mµ¹¤©ªvÀø¡A(3) ¦³®Ä¦aµ¹ªvÀø¤©¤j³¡¥÷ªº¨ü¼vÅT¤H¤f¡A(4) Àx¦s¨¬°÷ÃĪ«¡A(5) ¥þ¥Á¹ï«ÊÂ굦²¤¯S§O¬O¥ô¦óªÀ°Ï²¨»·ªkªº¦X§@¡A(6) °ê»Ú¶¡¦bµo®iµ¦²¤¡B¬Ì±¡ºÊ¹î©M±±¨î¹ïµ¦¹ê¬Iªº¦X§@¡C¦pªG·s¯f¬rªºRo¤j©ó1.8«K¤£¥i¯à¦¨¥\«ÊÂê¡C

¨Ï¥Î¬Û¦üªº¤èªk(Longini 2005)ªºÀH¾÷¬y·P¼ÒÀÀ¼Ò«¬´£¥X¦p¯àµ²¦X§Ü¯f¬r¥Ø¼Ð¹w¨¾ªk¡B¨Æ«e¬Ì­]±µºØ©M¹jÂ÷¥i±±¨îRo°ª¦Ü2.4ªº¯f¬r¡C¨Æ¹ê¤W¡A¥@½ÃÅwªï¤W­z»s³y³o¬y·PÃzµo¼Ò«¬ªº¤å¥ó(WHO 2005g)¡A¦ý¬OÃö©ó³o¼ÒÀÀ¼Ò«¬ÁÙ¬O¦³ÃöÁ䪺ª§ÅG¡C¨Ò¦p¦bLonginªº¤å³¹¤¤°²³]¶ø´µ¥L°¶¦bÃzµo®É¬O¾A¥Îªº¡A¦ý¶ø´µ¥L°¶¤£¬O¹ï©Ò¦³ªº¸V¬y·P³£¦³®Ä(Chung 2005)¡A¦³50%ªº®õ°ê¯f¤H¨Ï¥Î¶ø´µ¥L°¶¦ý¤]¨S¦³®Ä¤O(Fergusson 2005)¡C³B²z¤£Â_ºtÅܪº¸V¬y·P¯f¬r»Ý­n¤@­ÓÀ³«æ­p¹º¥h·Ç³Æ³ÌÃaªº±¡ªp¡A³o³ÌÃa±¡ªpªº¼Ò«¬´£¨Ñ¦³¥Îªº¸êªU¥Î¨Ó³W¹º¸ê·½¡A¨Ò¦p³q­·¾÷ªº¼Æ¥Ø¡B¯S§OÅ@²zªº¼Æ¶q¡A¬Æ¦Ü¬OÂl»öªº³]¬I(Chung 2005)¡C

¥H«eÃzµo´¿¨Ï¥Î¼W¥[ªÀ°Ï¶ZÂ÷ªk¡A§Y¨Ï¨ì²{¦b¤´¬O¤@­Ó­«­nªº¿ï¾Ü¥h­±¹ï±N¨ÓªºÃzµo(WHO 2005f)¡C³o¤èªk¥]¬A­­¨î®È¹C(¦bÃzµo¦a°Ïªº¤J¹Ò©M¥X¹Ò)¡BÃö³¬±Ð¨|³]¬I¡B¸T¤î¥Á²³»E·|¡B¹jÂ÷¨ü·P¬V¤H¤h©MºÃ¦ü¯f±wªÌ¡A¥[¤W¹jÂ÷´¿¼ÉÅS©ó¬y·PÃzµo¦a°Ïªº¤H¤h¤Î¹C«È(WHO 2005e)¡C³o¨Ç²¨»·¤èªkªº¦¨®ÄÁöµM¦bSARS¤@¬Ì¦¨¥\¡A¦ý¦b¬y·P¤WÀ³¥Î«h¦³ª§½×¡A¦]¬°SARS¯f¤H¦b¯f¼x¥X²{«e¨Ã¥¼¨ã¶Ç¬V©Ê¡A¦ý¬y·P¯f¤H¦b¯f¼x¥X²{«e¤w¨ã¶Ç¬V©Ê(Ho 2004)¡C

 

®Ú¾Ú¯gª¬ªº­Ó®×°l¬d

¬y·P³Q¹w´Á¬°Ãø¥H¥Î±µÄ²°l¬d«K¯à±±¨î¡A¦]¬°¬y·P¦b¯f¼x¥X²{«e¦³°ª«×ªº¶Ç¬V©Ê¡C¥t¥~¡A¬y·Pªº±µÄ²°l¬d¤j­P¤W³£¬O¤£¯à¹ê¦æ¡A¦]¬°¬y·Pªº¼ç¥ñ´Á(2¤é)©M·P¬V´Á(3-4¤é)«Üµu(Fraser 2004)¡C

 

Ãä¹Ò±±¨î

¦bSARSÃzµo´Á¶¡¡A¶q«×Åé·Å«Ü±`¥Î¦b¾÷«È¨­¤W¡A¦³µo¿Nªº¤H¤h·|³Q¸T¤îµn¾÷¡A¾÷³õªþªñªºÂå°|³Q«ü¬£¬°¦¬®e¡B¶EÂ_©MªvÀø¥ô¦óµo¿Nªº­¼«È(Ho 2004)¡A¦ý¬O¨Ï¥Î¬õ¥~½u±´´ú»ö¥u¯à±´´ú¤w¥X²{¯f¼xªº¬y·P¯f¤H¡C

 

½Ã¥Í»P®ø¬r

"©I§lªº½Ã¥Í"ªº«Øij¦n¹³«y¹Â®É±»¤f©MÁקK¦R·ð¦ü¥G¦³®Ä¡A¦ý¯Ê¥F¤ñ¹ï·Ó¬ã¨sªº¤ä«ù(CDC 2003)¡A¬y·P¯f¬r¯à¦bÀô¹Òªí­±¥Í¦s¨Ã¬Û«H¬O¥Ñ¤â¶Ç¼½(WHO 2006)¡A¤j³¡¥÷¦ý¤£¬O¥þ³¡ªº¹ï·Ó¬ã¨sµo²{¬~¤â¯à´î§C¤W©I§l¹D·P¬Vªº«OÅ@®ÄªG¡A¤j³¡¥÷ªº·P¬Vªº¬ã¨s³£¬O¥Ñ¯f¬r©Ò¤Þ°_ªº¡A¦ý¥u¦³¤Ö¼Æ¬ã¨s¬O¥Î¬y·P¯f¬r(Fasley 1999)¡C¦ü¥G¨S¦³¬ã¨s¬O¯S§O«ü©ú°w¹ï¬y·P¯f¬r(WHO 2006)¡C

 

­·ÀI³q°T

À³³]¥ß¤@­Ó­·ÀI³q°Tµ¦²¤¯à¦b¤£¦PÃzµo¶g´Á¦³¨¬°÷ªº¼u©Ê¼W¥[¨ä±j«×¡A­Ý¥BÀ³½T©w³Ì¾A¦X©M¦³®Ä¨Ã¥B¯à°÷¨Ï¥Îªº¶Ç´C¡C­n©ú´¼ªº¦bÃzµo¤§¶¡ªº¶g´Á½T»{¤@¦ì©x¤èµo¨¥¤H¡A¦b¤§«áªºÃzµo¶g´Á¡A³o¤H·|Ä~Äò¥LªºÂ¾³d¡C¸ê®Æ¨Ó·½À³¬O¤½²³¥i«H¤Î¥i±µ¨üªº¡A¨Ò¦p¥@½Ã¡B¯e¯f¨¾ªv¤¤¤ß©MÁp¦X°ê³­¹¤Î¹A·~²Õ´¡C²z·Qªºµo¨¥¤HÀ³¬OÅv«Â¤H¤h¡CÀ³ÁקK²£¥Í®£·W¡AµM¦Ó¹ê¥Îªº¸ê®ÆÀ³«O«ù¶}©ñµ¹©Ò¦³¤H(PPHSN 2004)¡C

 

µ²½×

¤@­Ó¥D­nªº¤j³W¼Ò¬y·PÃzµo·|³y¦¨·¥¤j¯}Ãa©Êªº«áªG¡A·|¹ï¤HÃþªº°·±d¡B¥þ²y¸gÀ٤Τj³¡¥÷°ê®aªº¬Fªv¤ÎªÀ·|í©w±a¨ÓµLªk¦ô­pªº¦M¾÷¡C°·¥þªº°]¬F¸ê·½¤Î¨}¦nªºÂåÀø³]³Æ©Î³\¯à´î»´³o¨Ç«áªG¡A¦ýµo®i¤¤°ê®a±N¥i¯à­±Á{§Ü¯f¬rÃĪ«¤£¨¬©Îµu¯Ê¡A¥H¤Î¨S¦³¾A·í¬Ì­]ªº°ÝÃD¡C

¦bµo®i¤¤°ê®aªº¬y·PÃzµo»P¤HÃþ¦b·í¦aªº±µÄ²¯f¬r²v¦³±K¤ÁÃö«Y¡C¦b³¡¥÷«D¬w¡B©Ô¤B¬ü¬w¤ÎªF«n¨È°ê®a¡A¤H­Ì·|»P®a¸VºÎ¦b¤@°_¡C¦bªF«n¨È¤Î¥H¥~ªº¦a¤è¡A¬¡®a¸V¥«³õ·|¤Þ°_¤HÃþ¶Ç¬Vªº¦MÀI(Webster 2004)¡C­n´î§C¤HÃþ¦b·í¦aªºÃz¥ú²v¡A±Ð¨|¤H­Ì¥¿½T®a¸V³B²zªº¤èªk¤Î§ïÅÜ¥@¬É¤W³\¦h¦a°Ïªº¤H­Ì¹ï¤H¸V¤¬°Êªº·§©À¬O¥²»Ýªº(World report 2005)¡C¦b¦³®Ä¹ï§ÜH5N1¯f¬rªº¤HÃþ¬Ì­]¥X²{«e¡A©ó¹w³Æ­¹ª«¤Î³B²z®a¸V®É§@¥X¤@¨Ç²³æªº¹wĵ±¹¬I¥H¤ÎÁקK¶¼¥Î¨ü¦Ã¬Vªº¤ô¬O¥²¶·ªº(Hayden 2005)¡C¦]¦¹¡A¦bµo®i¤¤°ê®a¹ï¬y·Pªº¨¾³Æ»Ý­n¦Ò¼{¨ì¹ï§ïÅܤH­Ì±Ð¾i¤Î§ïµ½½Ã¥Í©Ò»Ýªº¸êª÷¡C

¥Ñ¥@½Ã«ü¥X­n´î§C¬y·PÃzµo­·ÀIªº¤­­Ó¥²­n¦æ°Ê¥]¬A¡G

  • ´î¤Ö¦b·í¦aªº±µÄ²¯f¬r²v
  • ¼W±j§Ö³t¹K¨î¯f¬rªº¯à¤O(Àx³Æ¨¬°÷§Ü¯f¬rÃĪ«¥H¶i¦æ°w¹ï©Ê¹w¨¾¤ÎªÀ·|¹jÂ÷±¹¬I)
  • ¥[±j¤Î¦­¹wĵ¨t²Î
  • §Ö³t½Õ¬d¦³Ãö­Ó®×¤Î¸s²Õ
  • «Ø¥ß°ò¥»ªºÂåÀø¥i®e©Ê

¦pªG·s«¬¬y·P¯f¬rªº¶Ç¬V¦b¤HÃþµo¥Í¡A¬y·Pªº¶Ç¼½³t«×¨ú¨M©óµo²{¯f¬rªº®É¶¡©M°ê»ÚªÀ·|´©§Uªº³t«×¡A¥]¬A´£¨Ñ§Ü¯f¬rÃĪ«¨Ó¹w¨¾¯e¯f¡C°£¦¹¤§¥~ªº¥þ°ê·Ç³Æ­p¹º¡A¬F©²À³¿n·¥¦a´M¨D¾F°êªº¦X§@(Ho 2004)¡A«e¥@½ÃÁ`·F¨Æ§õÁ魧ĵ§i"¨S¦³°ê»Ú¶¡ªº¦X§@¡A¨S¦³°ê®a¥iµø¬°¦w¥þ"¡C

¥@½Ã©ó2005¦~11¤ë¦b¤é¤º¥Ëªº·|ij¡A´X­Ó§C¦¬¤J°ê®a¥Nªí¹ï¯Ê¥F«P¶i¥­µ¥¤À°tÃĪ«©M¬Ì­]ªº¦æ°Êªí¥ÜÃöª`¡AµL¼Æ°ê®a¦]³h½a¦Ó¤£¯à­t¾áÃĪ«©M¨S¦³¨¬°÷ªº­Ý®e©Ê¥h»s³y¬Ì­]©Î¤@¯ëªºÃĪ«(World Report 2005)¡C¦è¤è°ê®aÀx¦s§Ü¯f¬rÃĪ«©Mµo®i¬Ì­]¡A³o¥O§C¦Ü¤¤¦¬¤J°ê®a¾á¤ß¦o­Ì¨S¦³¿ìªk¥h¨Ï¥Î³o¨Ç¼ç¦bªº±Ï¥Í¤u¨ã¡C¦b³o­Ó·|ij¤¤¡A¨S¦³¤@¥÷«Øij®Ñª½±µ«ü¥X¦bÃzµo®É¥­µ¥¨Ï¥ÎÃĪ«©M¬Ì­]ªº°ÝÃD(Enserink 2005)¡C

¦è¤è°ê®a¹ïµo®i¤¤°ê®aªº¤ä´©À³°ª©ó¥u¹ï¥I¬Ì¯g¡A¬Ì¯g¤@¦ýµo¥Í¡A¨º«K¤Ó¿ð¡C¬Ì¯g¤j³W¼ÒÃzµo¨Ã¨S¦³Ãä¬É¡A©Ò¥H°ê»Ú¶¡ªº¦X§@©M¥­§¡¤À°t¸ê·½À³ºÉ§Ö¹ê¬I¡C

¸ê®Æ

  1. ACIP 2005. Recommendations of the Advisory Committee on Immunization Practices (ACIP). July 13, 2005 / 54 (Early Release); 1-40. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr54e713a1.htm
  2. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford Univ. Press, Oxford, 1992.
  3. Axbbott A. Avian flu special:  What's in the medicine cabinet? Nature 435;407-409. Available from http://www.nature.com/nature/journal/v435/n7041/full/435407a.html
  4. Balicer RD, Huerta M, Davidovitch N, Grotto I. Cost-benefit of stockpiling drugs for influenza pandemic. Emerg Infect Dis 2005; 11: 1280-2. Full text at http://www.cdc.gov/ncidod/EID/vol11no08/04-1156.htm
  5. Barnett DJ, Balicer RD, Lucey DR, et al. A systematic analytic approach to pandemic influenza preparedness planning. PLoS Med 2005; 2: 1-7. Full text at http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/jour nal.pmed.0020359
  6. Brett AS, Zuger A. The run on tamiflu - should physicians prescribe on demand? N Engl J Med 2005; 353: 2636-37. Full text at http://content.nejm.org/cgi/content/full/353/25/2636
  7. Brown H. Nations set out a global plan for influenza action. Lancet 2005; 366: 1684-5.
  8. BWHO 2004. World is ill-prepared for "inevitable" flu pandemic. Bull World Health Organ 2004; 82:317-318.
  9. CDC 2003. Centers for Disease Control and Prevention. Respiratory hygiene/cough etiquette in healthcare settings 2003 Dec 17 [cited 2005 Nov 18]. Available at: http://www.cdc.gov/flu/professionals/infectioncontrol/resphygiene.htm
  10. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005; 11: 201-9. Full text at http://www.cdc.gov/ncidod/eid/vol11no02/04-1061.htm
  11. Chung PH. Preparing for the worst-case scenario. Science 2005; 310:1117-8.
  12. CP/BSB 2003. Clinical Pharmacology/Biopharmaceutics Summary Background 2003. http://www.fda.gov/cder/foi/esum/2004/21246slr010,21087slr016_Tamiflu_Pharm_Biopharm _BPCA.pdf
  13. de Jong MD, Thanh TT, Khank TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-72. Full text at http://content.nejm.org/cgi/content/full/353/25/2667
  14. Enserink M. Meeting seeks global consensus, highlights global disparities. Science 2005; 310: 1103.
  15. Fal Falsey AR, Criddle MM, Kolassa JE, McCann RM, Brower CA, Hall WJ. Evaluation of a handwashing intervention to reduce respiratory illness rates in senior day-care centers. Infect Control Hosp Epidemiol 1999; 20: 200-2. Abstract: http://amedeo.com/lit.php?id=10100548
  16. FAO 2005. FAO Avian influenza disease emergency. Update on the avian influenza situation (as of 12/11/2005) - Issue no. 36. Available at: http://www.fao.org/ag/againfo/subjects/documents/ai/AVIbull036.pdf
  17. FAO, OIE, WHO 2005. A Food and Agriculture Organisation (FAO), World Organisation for Animal Health (OIE) in collaboration with World Health Organisation (WHO) Global Strategy for the Progressive Control of Highly Pathogenic Avian Influenza (HPAI). November 2005. Available at: http://www.fao.org/ag/againfo/resources/documents/empres/AI_globalstrategy.pdf
  18. Ferguson NM, Cummings DA, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005; 437: 209-14. Abstract: http://amedeo.com/lit.php?id=16079797
  19. Ferguson NM, Fraser C, Donnelly CA, Ghani AC, Anderson RM. Public health risk from the avian H5N1 influenza epidemic. Science 2004; 304: 968-69.
  20. Flahault A, Dias-Ferrao V, Chaberty P, Esteves K, Valleron AJ, Lavanchy D. Flu Net as a tool for global monitoring of influenza on the Web. JAMA 1998; 280: 1330-2. Full text at http://jama.ama-assn.org/cgi/content/full/280/15/1330
  21. Fleming D. Influenza pandemics and avian flu. BMJ 2005;331:1066-9.
  22. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. PNAS 2004; 101: 6146-51. Full text at http://www.pnas.org/cgi/content/abstract/101/16/6146
  23. Groeneveld K, van der Noordaa J. Use of antiviral agents and other measures in an influenza pandemic. The Neth J Med 2005; 63: 339-43. Full text at http://www.zuidencomm.nl/njm/getpdf.php?id=437
  24. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183: 523-31. Full text at http://www.journals.uchicago.edu/JID/journal/issues/v183n4/000943/000943.html
  25. Hayden F, Croisier A. Transmission of Avian Influenza Viruses to and between Humans. The J Infec Dis 2005; 192: 1311-4.
  26. Hayden FG. Antivirals for pandemic influenza. J Infect Dis 1997; 176: Suppl 1: Abstract: http://amedeo.com/lit.php?id=9240696
  27. Hien TT, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350: 1179-88. Full text at http://content.nejm.org/cgi/content/abstract/350/12/1179
  28. Ho MS, Su IJ. Preparing to prevent severe acute respiratory syndrome and other respiratory infections. Lancet Infect Dis 2004; 4: 684-9. Abstract: http://amedeo.com/lit.php?id=15522680
  29. Hoffmann C, Kamps BS. Drugs. In: Influenza Report 2006; Wuppertal 2006. Available from http://InfluenzaReport.com/ir/drugs.htm
  30. Hoffmann C, Korsman S, Kamps BS. Treatment and Prophylaxis. In: Influenza Report 2006; Wuppertal 2006. Available from http://InfluenzaReport.com/ir/tp.htm
  31. IHR 2005. International Health Regulations 2005. Available at: http://www.who.int/gb/ebwha/pdf_files/WHA58/WHA58_3-en.pdf
  32. Imuta F, Toyoda M, Toyoda T. New application method of zanamivir with a straw. Pediatr Int 2003; 45: 366-7.
  33. Johnson NP, Mueller J. Updating the accounts: Global mortality of the 1918-20 "Spanish" influenza pandemic. Bull Hist Med 2002; 76: 105-15. Abstract: http://amedeo.com/lit.php?id=11875246
  34. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 759-65. Abstract: http://amedeo.com/lit.php?id=15337401
  35. Korsman S. Vaccines. In: Influenza Report 2006; Wuppertal 2006. Available from http://InfluenzaReport.com/ir/vaccines.htm
  36. Lipatov AS, Govorkova EA, Webby RJ, et al. Influenza: emergence and control. J Virol 2004; 78: 8951-9. Full text at http://jvi.asm.org/cgi/content/full/78/17/8951?view=long&pmid=15308692
  37. Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004; 159: 623-33. Abstract: http://amedeo.com/lit.php?id=15033640
  38. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME. Containing pandemic influenza at the source. Science. 2005 Aug 12;309(5737):1083-7.
  39. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264-72. Full text at http://aac.asm.org/cgi/content/full/47/7/2264?view=long&pmid=12821478
  40. Moscona A. Oseltamivir resistance--disabling our influenza defenses. N Engl J Med 2005; 353: 2633-6. http://amedeo.com/lit.php?id=16371626 - Full text at http://content.nejm.org/cgi/content/full/353/25/2633
  41. Osterholm MT. Preparing for the next pandemic. N Engl J Med 2005; 352: 1839-42. Full text at http://content.nejm.org/cgi/content/full/352/18/1839
  42. PPHSN 2004. Pacific Public Health Surveillance Network Guidelines for Influenza Preparedness & Control and Influenza Pandemic Preparedness (Part II). Prepared in Consultation with the PPHSN Influenza Specialist Group (ISG). Available at: http://www.spc.org.nc/phs/pphsn/Publications/Guidelines/Influenza/PPHSN_Influenza_pa ndemic-guidelines-partII-final_draft-oct04.pdf
  43. Stilianakis NI, Perelson NS, Hayden FG. Drug resistance and influenza pandemics. Lancet 2002; 359: 1862-3.
  44. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437: 889-93. Full text at http://www.nature.com/nature/journal/v437/n7060/pdf/nature04230.pdf
  45. Thanhnien 2005. http://www.thanhniennews.com/healthy/?catid=8&newsid=10854
  46. USDHHS 2005. United States Department of Health and Human Services 2005. Draft pandemic influenza preparedness and response plan. Annex 9: Communication and education. Available at: http://www.hhs.gov/nvpo/pandemicplan/annex9.communication.pdf
  47. van Dalen PJ, Wijdenes C. Preparing for the next influenza pandemic. Neth J Med 2005; 63: 337-8. Full text at: http://www.zuidencomm.nl/njm/getpdf.php?id=436
  48. Vardi A, Levin I, Berkenstadt H, et al. Simulation-based training of medical teams to manage chemical warfare casualties. Isr Med Assoc J 2002; 4: 540-4. Abstract: http://amedeo.com/lit.php?id=12120468
  49. WCWHO 2005. The Writing Committee of the World Health Organisation (WHO) Consultation on Human Influenza A/H5. Avian Influenza A (H5N1) Infection in Humans. N Engl J Med 2005; 353: 1374-85. Full text at http://content.nejm.org/cgi/content/full/353/13/1374
  50. Webster RG, Peiris M, Chen H, Guan Y. H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 2006; 12: 3-8. Available at: http://www.cdc.gov/ncidod/EID/vol12no01/05-1024.htm
  51. Webster RG. Wet markets--a continuing source of severe acute respiratory syndrome and influenza? Lancet. 2004 Jan 17;363(9404):234-6.
  52. WHO 2004: Informal consultation on influenza pandemic preparedness in countries with limited resources. Kuala Lumpur, Malaysia 23-25 June 2004. Department of Communicable Disease Surveillance and Response. http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2004_1/en/in dex.html
  53. WHO 2005a: Geographical spread of H5N1 avian influenza in birds - update 28. Situation assessment and implications for human health. 18 August 2005. http://www.who.int/entity/csr/don/2005_08_18/en/index.html
  54. WHO 2005b: Geographical Spread of H5N1 in Birds-update 34: 20 October 2005. http://www.who.int/csr/don/2005_08_18/en/index.html
  55. WHO 2005c: Situation Updates: Accessed on January 25, 2006. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_01_25/en/ind ex.html
  56. WHO 2005d: WHO global influenza preparedness plan: The role of WHO and recommendations for national measures before and during pandemics. Available at: http://www.who.int/entity/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_ 5/en/index.html
  57. WHO 2005e: Checklist for influenza pandemic preparedness planning 2005. http://www.who.int/csr/resources/publications/influenza/FluCheck6web.pdf
  58. WHO 2005f: Avian influenza: assessing the pandemic threat. http://www.who.int/csr/disease/influenza/WHO_CDS_2005_29/en/index.html.
  59. WHO 2005G: WHO Statement. Available at: http://www.who.int/mediacentre/news/statements/2005/s08/en/index.html
  60. WHO 2006. World Health Organisation Writing Group. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006; 12: 81-7. Full text at http://www.cdc.gov/ncidod/EID/vol12no01/05-1370.htm
  61. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49: 4075-84. Abstract: http://amedeo.com/lit.php?id=16189083
 

 

Department of Biochemistry, The Chinese University of Hong Kong © 2006